









Markets
/
Stocks
/
nasdaq-tvtx
/

Travere Therapeutics Inc

TVTX

24.850USD

+0.660+2.73%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

2.21BMarket Cap

LossP/E TTM



Travere Therapeutics Inc

24.850

+0.660+2.73%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

13 / 506

Overall Ranking

82 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Buy

Current Rating

36.462

Target Price

+50.73%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 113.02% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 15.46.

Undervalued

The company’s latest PE is -12.34, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 104.47M shares, decreasing 9.92% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 5.98M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.90, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 114.45M, representing a year-over-year increase of 111.49%, while its net profit experienced a year-over-year increase of 81.88%.

Score

Industry at a Glance

Previous score

7.90

Change



Financials

5.18

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.67

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -12.01, which is -65.45% below the recent high of -4.15 and 55.22% above the recent low of -5.38.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 13/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.53, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Travere Therapeutics Inc is 35.00, with a high of 47.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

8.53

Change

Support & Resistance

No Data

Analyst Rating

Based on 15 analysts

Buy

Current Rating

36.462

Target Price

+50.73%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Travere Therapeutics Inc

TVTX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.04, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 29.57 and the support level at 17.93, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.04

Change

0.1

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.397

Buy

RSI(14)

66.939

Neutral

STOCH(KDJ)(9,3,3)

46.409

Neutral

ATR(14)

1.731

High Vlolatility

CCI(14)

65.181

Neutral

Williams %R

33.641

Buy

TRIX(12,20)

1.512

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

23.694

Buy

MA10

23.709

Buy

MA20

21.143

Buy

MA50

18.479

Buy

MA100

17.581

Buy

MA200

18.276

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 117.23%, representing a quarter-over-quarter increase of 2.23%. The largest institutional shareholder is The Vanguard, holding a total of 5.98M shares, representing 6.70% of shares outstanding, with 12.84% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

7.53M

+85.50%

Armistice Capital LLC

8.87M

+20.58%

BlackRock Institutional Trust Company, N.A.

6.72M

+1.27%

The Vanguard Group, Inc.

Star Investors

5.00M

-25.73%

Macquarie Investment Management

4.80M

+12.62%

State Street Global Advisors (US)

3.65M

-3.20%

Emerald Advisers LLC

3.20M

-0.88%

Adage Capital Management, L.P.

2.18M

+479.86%

Renaissance Technologies LLC

Star Investors

2.70M

+12.17%

Geode Capital Management, L.L.C.

1.98M

+7.29%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.96, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.80. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.